Merck & Co., Inc. And Nicaragua Unveil New Rotavirus Vaccine Demonstration Project At Clinton Global Initiative; Merck & Co., Inc. Will Provide Free Rotavirus Vaccine For All Infants Born In Nicaragua Over The Next Three Years, A $75 Million Commitment

NEW YORK--(BUSINESS WIRE)--Sept. 22, 2006--Merck & Co., Inc. and the Nicaraguan Ministry of Health today announced plans to conduct a joint project aimed to demonstrate the public health impact of implementing a full rotavirus vaccination program in Nicaragua. Through this project, all infants born in Nicaragua in a three-year period will receive free doses of ROTATEQ(R) (rotavirus vaccine, live, oral, pentavalent), Merck's oral, ready-to-use vaccine to prevent rotavirus gastroenteritis in infants and young children when given in a three-dose series to infants between the ages of six to 32 weeks. In addition to providing ROTATEQ, Merck will also provide technical assistance for the duration of the program.

Back to news